Chronic Obstructive Pulmonary Disease Case Finding in Community-pharmacies by Spirometry (FARMAEPOC)

Col·legi de Farmacèutics de la Província de Barcelona

Status and phase: Unknown; Early Phase 1

Conditions: Chronic Obstructive Pulmonary Disease

Treatments: Other: Spirometry

Study type: Interventional

Funder types: Other

Identifiers

NCT01576068

2008/3128/I

Details and patient eligibility

About

Chronic Obstructive Pulmonary Disease (COPD) is a prevalent disease. In the investigators country, underdiagnosis has been estimated in around 80% of subjects. Early detection is done mainly in primary care but due to actual situation new alternatives have been proposed to decrease underdiagnosis.

This present study promote by a multidisciplinary research team (respiratory medicine, primary care, nurse and pharmacist) raise the objective of evaluate the effect of a COPD case finding program guide by spirometry in community-pharmacies.

From the results of a pilot-study conducted in 13 community-pharmacies in Barcelona, in which the investigators showed the feasibility of spirometry in community-pharmacies for the early detection of COPD, the investigators have design a second phase to evaluate the effect of this strategy. 100 Barcelona's community-pharmacies during 6 months will select high risk customers and will conduct a spirometry in agreement with the design protocol. 3600 spirometries is the establish objective. Participants hospitals will train pharmacist in spirometry and also control spirometry quality daily by a telematic pathway. Spirometry results will be evaluate in terms of effect and costs. The investigators will also evaluate the impact of this program in the health system by numbers of subjects diagnosed and follow up in primary care.

Enrollment: 3,600 estimated patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age over 40 years.
• Current or former smoker
• Chronic respiratory symptoms(cough, shortness of breath, expectoration)

Exclusion criteria

• Previous diagnosed chronic lung disease
• Use of inhalers

Trial design

Primary purpose: Screening

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

3,600 participants in 1 patient group

High Risk Customers

Other group

Description:

Pharmacy customers with GOLD COPD Criteria of high-risk subjects.

Treatment:

Other: Spirometry